Sign in

CURX on Nasdaq

Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is an American pharmaceutical preparations company, incorporated in Nevada.1 It is headquartered in Jericho, New York.1 Its shares trade on Nasdaq under the symbol CURX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCURX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersJericho, New York1
  • Incorporated inNV2
  • Business address2 Jericho Plaza,, Suite101B, Jericho, Ny 117532
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$4.2M in 2025+1061% since 2024
-$6.0M-$4.0M-$2.0M02024: -$365.1K-$365.1K20242025: -$4.2M-$4.2M2025+1061%
Net income3-$4.2M in 2025+1069% since 2024
-$6.0M-$4.0M-$2.0M02024: -$361.5K-$361.5K20242025: -$4.2M-$4.2M2025+1069%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
General & Administrative$1.3M$290.4K
IP Development Impairments$74.7K
Research & Development$3.0M
Total Operating Expenses$4.2M$365.1K
Loss from Operations-$4.2M-$365.1K
Interest Expense-$8.5K
Other Income$22.5K$3.6K
Net Loss-$4.2M-$361.5K
Net loss per common share: Basic-$0.17-$0.03
Net loss per common share: Diluted-$0.17-$0.03
Weighted average number of common shares outstanding: Basic25.5M shares13.3M shares
Weighted average number of common shares outstanding: Diluted25.5M shares13.3M shares

Compare Curanex Pharmaceuticals Inc with another company

What it owns

What Curanex Pharmaceuticals Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$352.6K3 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.0M3 Dec 31, 2025

Properties, in its own words

Our principal executive offices are located at 2 Jericho Plaza, Suite 101B, Jericho, NY 11753. Our telephone number is (718) 673-6078. Our website address is www.curanexpharma.com. Information contained on our website or connected thereto does not constitute part of, and is not incorporated by reference into, this annual report on Form 10-K of which it forms a part.

Item 2 of the 10-K filed Mar 30, 2026.6

Leadership

Who has led Curanex Pharmaceuticals Inc, and when. Pick a name to see everywhere that person has worked.

Chief operating officer

  1. Liqin Xie2025–now
  • Chief operating officerLiqin Xie Sep 2, 2025 to now7
Board members and other officers (6)

Timeline

  1. Sep 4, 20268-K Other events13
  2. Aug 17, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed14
  3. May 14, 20268-K Regulation FD disclosure15
  4. May 7, 20268-K Other events16
  5. Apr 2, 20268-K Regulation FD disclosure17
  6. Mar 6, 20268-K Entered a material agreement; Executive or director change18
  7. Jan 5, 20268-K Executive or director change19
  8. Nov 6, 20258-K Listing notice or transfer20
  9. Sep 29, 20258-K Unregistered sale of shares; Other events21
  10. Sep 12, 20258-K Other events22
  11. Aug 27, 20258-K Other events23
  12. Aug 26, 20258-K Entered a material agreement; Other events24

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/202625

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

63 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 12 major events, 9 insider forms, 37 other. The latest 20:

  1. Sep 4, 20268-K EDGAR
  2. Aug 17, 20268-K EDGAR
  3. Aug 14, 202610-Q EDGAR
  4. Jul 21, 2026S-8 EDGAR
  5. Jun 29, 2026DEF 14C EDGAR
  6. Jun 18, 2026PRE 14C EDGAR
  7. May 14, 20268-K EDGAR
  8. May 14, 202610-Q EDGAR
  9. May 7, 20268-K EDGAR
  10. Apr 2, 20268-K EDGAR
  11. Mar 30, 202610-K EDGAR
  12. Mar 6, 20268-K EDGAR
  13. Jan 5, 20268-K EDGAR
  14. Nov 17, 202510-Q EDGAR
  15. Nov 17, 2025NT 10-Q EDGAR
  16. Nov 6, 20258-K EDGAR
  17. Sep 29, 20258-K EDGAR
  18. Sep 12, 20258-K EDGAR
  19. Sep 9, 202510-Q EDGAR
  20. Sep 2, 20253 EDGAR

The 63 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Curanex Pharmaceuticals Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCuranex Pharmaceuticals Inc1
  • CIK0002025942
  • Employer ID (EIN)83-07413906
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company6
  • Incorporated inNevada6
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2 Jericho Plaza,, Suite101B, Jericho, NY 117531
  • Phone718-673-60781
  • Shares outstanding31,364,812 as of Aug 14, 20265
  • Public float$0 as of Jun 30, 20253
  • AuditorKreit & Chiu CPA LLP, Los Angeles, California PCAOB ID 6651; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceJun 20, 20241
  • Filings63 in all: 8-K (12), 3 (9), CORRESP (8), S-1/A (6), UPLOAD (5), 10-Q (4), FWP (3), 424B4 (2)1
    All 20 form types

    DRS/A (2), DRSLTR (2), 10-K (1), 8-A12B (1), CERT (1), DEF 14C (1), DRS (1), EFFECT (1), NT 10-Q (1), PRE 14C (1), S-1 (1), S-8 (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Latest 8-K (8-K) Sep 4, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par valueCURXNASDAQ

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks Curanex Pharmaceuticals Inc names in Item 1A of its 10-K filed Mar 30, 2026: 40 risks under these headings, as written.6

  • Risks Related to Our Business
  • We have a limited operating history in an evolving industry, which makes it difficult to evaluate our future prospects and may increase the risk that we will not be successful.
  • If we fail to raise capital when needed it will have a material adverse effect on our business, financial condition and results of operations.
  • Risks Related to Protection of Intellectual Property Rights
  • If we are unable to obtain patent protection for our lead product candidate, to successfully develop and commercialize Phyto-N, our ability to sustain future operations will be significantly diminished.
  • Any failure in our clinical trials could impair the commercial prospects for our development of Phyto-N.
  • Our success is largely dependent on our ability to obtain and maintain patent protection and preserve trade secrets, which cannot be guaranteed. Failure to obtain and maintain effective registration of non-provisional utility patents in the United States will have a significant adverse effect on our business.
  • Claims by other companies that we infringe on their proprietary technology may result in liability for damages or stop our development and commercialization efforts.
  • We may be subject to substantial costs stemming from our defense against third-party intellectual property infringement claims.
  • We may enter into collaboration agreements for the development of products and business development, which could expose us to the risk of reliance on the viability of third parties.
  • There is no assurance we will be profitable.
  • We may not have the ability to manage its growth.
The other 30 risks
  • We may engage in acquisition activity, which could have adverse effects on its business.
  • We will rely on third parties for the manufacturing of our clinical drug supplies, and we may face various risks and uncertainties based on our dependence on these manufacturers, which may impair the development of our drug candidates.
  • We rely on the performance of highly skilled personnel, and if we are unable to attract, retain and motivate well-qualified employees, our business could be harmed.
  • Our management does not have experience as senior management of a public company or ensuring compliance with public company obligations, and fulfilling these obligations will be expensive and time consuming, which may divert management’s attention from the day-to-day operation of its business.
  • We may become a party to various legal proceedings, which could have a material adverse effect on our business, financial condition or results of operations.
  • We may be subject to personal injury, workers’ compensation, discrimination, harassment, wrongful termination, wage and hour, and other claims in the ordinary course of business.
  • Risks Related to the Regulation of Our Business and Products
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • We are heavily dependent on the success of Phyto-N, our lead product candidate, Phyto-N. We cannot give any assurance that Phyto-N will proceed to clinical development or that it will receive regulatory approval, which is necessary before we can commercialize it.
  • The development and approval process for botanical drugs involves unique challenges and regulatory considerations that may result in additional costs, delays, or failure to obtain regulatory approval.
  • We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
  • We may fail to sufficiently and promptly respond to clinical demand and market changes in the pharmaceutical industry.
  • We face risks related to compliance with corporate governance laws and financial reporting standards.
  • Our systems and infrastructure face certain risks, including cybersecurity and data leakage risks. failure or disruption in or to our information system could compromise sensitive information related to our business and expose us to liability or reputational harm, and our ability to effectively manage our business operations could be adversely affected.
  • Events such as natural disasters, industrial accidents, epidemics, pandemics, war and acts of terrorism, and adverse weather conditions could disrupt our business or the business of our customers, which could significantly harm our operations, financial results and cash flow.
  • Changes to U.S. tariff and import/export regulations and inflation may adversely affect our operations and financial results.
  • Risks Relating to Ownership of Our Securities.
  • We may not be able to satisfy the listing requirements of Nasdaq to maintain a listing of our Common Stock.
  • If our Common Stock becomes subject to the penny stock rules, it may be more difficult to sell our Common Stock.
  • A possible “short squeeze” due to a sudden increase in demand of our Common Stock that largely exceeds supply may lead to price volatility in our Common Stock.
  • Our founders will continue to own a significant percentage of our Common Stock and our Series A Preferred Stock and will be able to exert significant control over matters subject to shareholder approval.
  • The Company incurs significant increased expenses and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of operations.
  • Prior to the closing of the IPO there was no public market for our Common Stock, and there is no assurance that an active market for our Common Stock may develop.
  • Our failure to maintain effective internal controls over financial reporting could have an adverse impact on us.
  • Our financial controls and procedures may not be sufficient to ensure timely and reliable reporting of financial information, which, as a public company, could materially harm our stock price.
  • We must implement additional and expensive procedures and controls in order to grow our business and organization and to satisfy new reporting requirements, which will increase our costs and require additional management resources.
  • We are an “emerging growth company” under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
  • As a “controlled company” under the rules of Nasdaq, we may choose to exempt our Company from certain corporate governance requirements that could have an adverse effect on our public shareholders.
  • We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

Legal proceedings

We are not aware of any pending legal proceedings to which we are a party, or to which any director, officer or affiliate of our Company, or any owner of record or beneficially of more than 5% of any class of our voting securities, is a party adverse to us or has a material interest adverse to us.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
    SEC EDGAROther events
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25